Pharmaceutical

BMS and 2seventy bio’s Abecma gains approval for multiple myeloma

Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma have received FDA approval for relapsed or refractory multiple myeloma (RRMM).

Apr 9, 2024 - 00:00
BMS and 2seventy bio’s Abecma gains approval for multiple myeloma
Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma have received FDA approval for relapsed or refractory multiple myeloma (RRMM).
Read the original article

Tags:

Previous Article

Medicxi and Starpharma to develop dendrimer-based cancer treatments

Next Article

FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for solid tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

Amneal’s CREXONT gains FDA approval for Parkinson’s tre...

Aug 9, 2024

As midwife-assisted home births rise, so too do high-risk births outside hospitals

As midwife-assisted home births rise, so too do high-ri...

Feb 23, 2024

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

FDA approves Accord BioPharma’s HERCESSI for cancer tre...

Sep 20, 2024